Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature.

Abstract

Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder characterized by a malignant proliferation of plasma cells in blood and bone marrow. Treatment of primary PCL has been mostly disappointing. Three patients with primary PCL are described who received high-dose melphalan with autologous PBSC support after vincristine, doxorubicine and dexamethasone (VAD), high-dose cyclophosphamide, and etoposide, cisplatinum, dexamethasone and cytosine arabinoside (EDAP) courses. All patients were in CR post-transplantation. One patient relapsed after 3 months; the other patients are still in CR, after 14 and 26 months, respectively. These results in conjunction with data from the literature suggest that intensive chemotherapy for PCL is promising.

• Authors: S Hovenga, J T de Wolf, H Klip, E Vellenga
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 20 Issue 10 Pg. 901-4 (Nov 1997) ISSN: 0268-3369 [Print] England
• PMID: 9404934 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Paraproteins
• Cytarabine
• Vincristine
• Etoposide
• Dexamethasone
• Doxorubicin
• Cisplatin
• Melphalan

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cisplatin (administration & dosage)
• Combined Modality Therapy
• Cytarabine (administration & dosage)
• Dexamethasone (administration & dosage)
• Doxorubicin (administration & dosage)
• Etoposide (administration & dosage)
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Plasma Cell (blood, therapy)
• Melphalan (administration & dosage)
• Middle Aged
• Paraproteins (analysis)
• Remission Induction
• Treatment Outcome
• Vincristine (administration & dosage)